Imagine this scene: Republicans call a hearing to discuss how a federal agency handles a regulated industry. Company executives and government bureaucrats are present. Then the elected representatives from the party of small government don't tee up any questions for industry to offer its preferred solutions to the problems it sees with current regulations.
That's the situation the generic industry found itself in during a March 2 hearing by House Energy & Commerce Subcommittee on Health, and it suggests that reforms to Risk Evaluation and Mitigation Strategies (REMS)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?